AU2005278962C1 - Isoindolin-1-one derivatives - Google Patents

Isoindolin-1-one derivatives Download PDF

Info

Publication number
AU2005278962C1
AU2005278962C1 AU2005278962A AU2005278962A AU2005278962C1 AU 2005278962 C1 AU2005278962 C1 AU 2005278962C1 AU 2005278962 A AU2005278962 A AU 2005278962A AU 2005278962 A AU2005278962 A AU 2005278962A AU 2005278962 C1 AU2005278962 C1 AU 2005278962C1
Authority
AU
Australia
Prior art keywords
mmol
nmr
substituted
phenyl
dihydroisoindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005278962A
Other languages
English (en)
Other versions
AU2005278962A1 (en
AU2005278962B2 (en
Inventor
Alan H. Calvert
Bernard Thomas Golding
Roger John Griffin
Ian Robert Hardcastle
Per Kallblad
John Lunec
David R. Newell
Martin E. M. Nobel
Hendrika Maria Gerarda Willems
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2005278962A1 publication Critical patent/AU2005278962A1/en
Publication of AU2005278962B2 publication Critical patent/AU2005278962B2/en
Application granted granted Critical
Publication of AU2005278962C1 publication Critical patent/AU2005278962C1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2005278962A 2004-09-02 2005-08-26 Isoindolin-1-one derivatives Expired AU2005278962C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0419481.7 2004-09-02
GBGB0419481.7A GB0419481D0 (en) 2004-09-02 2004-09-02 Isoindolin-1-one derivatives
PCT/GB2005/003345 WO2006024837A1 (en) 2004-09-02 2005-08-26 Isoindolin-1-one derivatives

Publications (3)

Publication Number Publication Date
AU2005278962A1 AU2005278962A1 (en) 2006-03-09
AU2005278962B2 AU2005278962B2 (en) 2012-03-01
AU2005278962C1 true AU2005278962C1 (en) 2012-10-25

Family

ID=33155907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005278962A Expired AU2005278962C1 (en) 2004-09-02 2005-08-26 Isoindolin-1-one derivatives

Country Status (7)

Country Link
US (1) US8258175B2 (enExample)
EP (1) EP1786773B1 (enExample)
JP (1) JP5057273B2 (enExample)
AU (1) AU2005278962C1 (enExample)
CA (1) CA2578955A1 (enExample)
GB (1) GB0419481D0 (enExample)
WO (1) WO2006024837A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101405285B (zh) * 2006-03-22 2012-10-10 詹森药业有限公司 作为mdm2和p53间相互作用的抑制剂的环状-烷基胺衍生物
ATE470665T1 (de) * 2006-03-22 2010-06-15 Janssen Pharmaceutica Nv Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
WO2007139499A1 (en) * 2006-05-31 2007-12-06 Aprea Ab Compounds for use as a medicament
WO2008072655A1 (ja) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited イミダゾチアゾール誘導体
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
GB0811643D0 (en) * 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
RU2553269C2 (ru) 2009-11-12 2015-06-10 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Спирооксиндольные антагонисты mdm2
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP2014500870A (ja) 2010-11-12 2014-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
TR201807311T4 (tr) 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
TW201321371A (zh) 2011-10-14 2013-06-01 Incyte Corp 做為ａｋｔ抑制劑之異吲哚啉酮及吡咯并吡啶酮衍生物
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP3004109A1 (en) 2013-05-27 2016-04-13 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
EA028035B1 (ru) 2013-05-28 2017-09-29 Новартис Аг Производные пиразолопирролидин-4-она и их применение при лечении заболевания
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2015075665A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
CN107427501B (zh) 2015-02-20 2023-12-01 第一三共株式会社 通过联合使用治疗癌症的方法
TWI697329B (zh) 2015-04-13 2020-07-01 日商第一三共股份有限公司 血液癌症治療用之醫藥及其用途
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｍｄｍ２タンパク質分解剤
US20190240210A1 (en) 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN107286074B (zh) * 2017-08-16 2019-08-20 厦门华厦学院 3-羟基异吲哚-1-酮衍生物及其制备方法
JP7322036B2 (ja) 2018-01-08 2023-08-07 ケモセントリックス，インコーポレイティド Ｃｃｒ６またはｃｘｃｒ２のアンタゴニストを用いて汎発性膿疱性乾癬を治療する方法
CN109053546B (zh) 2018-07-05 2021-04-27 中国科学院兰州化学物理研究所 一种苯酞类衍生物及其制备方法和应用
BR112021006647A2 (pt) 2018-10-08 2021-07-13 The Regents Of The University Of Michigan degradores de proteína mdm2 de pequenas moléculas
EP3659964A1 (en) 2018-11-28 2020-06-03 Hysilabs, SAS Catalysed process of production of hydrogen from silylated derivatives as hydrogen carrier compounds
PH12022552056A1 (en) 2020-02-07 2024-02-12 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
MX2022011602A (es) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325066A (en) * 1970-02-12 1973-08-01 American Home Prod Phthalimidine compounds
US3763178A (en) * 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
US4200759A (en) * 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) * 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
GB1601701A (en) * 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4331600A (en) * 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4505921A (en) * 1982-09-23 1985-03-19 Adir, S.A.R.L. Sulfonylurea compounds and their use in treating diabetes
US6344468B1 (en) * 1998-02-21 2002-02-05 Aventis Pharma Deutschland Gmbh Substituted isoindolones and their use as cyclic GMP modulators in medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3466298A (en) * 1967-03-14 1969-09-09 American Home Prod Process for the preparation of 2-(2-aminoethyl)isoindolines
AR203991A1 (es) * 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
FR2217000B1 (enExample) * 1973-02-08 1976-04-09 Rhone Poulenc Ind
DE2840800C2 (de) * 1978-09-20 1980-02-14 Mannesmann Demag Ag, 4100 Duisburg Kanalbaumaschine
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
WO2001032928A2 (en) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
AU2002366278B2 (en) * 2001-12-18 2007-07-19 F. Hoffmann-La Roche Ag CIS-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
JP2004217591A (ja) * 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
JP2005255660A (ja) * 2004-03-10 2005-09-22 Katsuhiko Tomooka 多官能基を有するラクタム類とその製法
CA2565200C (en) * 2004-05-07 2013-12-24 Exelixis, Inc. Raf modulators and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763178A (en) * 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
GB1325066A (en) * 1970-02-12 1973-08-01 American Home Prod Phthalimidine compounds
GB1601701A (en) * 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4200759A (en) * 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) * 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
US4331600A (en) * 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4505921A (en) * 1982-09-23 1985-03-19 Adir, S.A.R.L. Sulfonylurea compounds and their use in treating diabetes
US6344468B1 (en) * 1998-02-21 2002-02-05 Aventis Pharma Deutschland Gmbh Substituted isoindolones and their use as cyclic GMP modulators in medicaments

Also Published As

Publication number Publication date
EP1786773B1 (en) 2017-03-01
WO2006024837A1 (en) 2006-03-09
AU2005278962A1 (en) 2006-03-09
CA2578955A1 (en) 2006-03-09
GB0419481D0 (en) 2004-10-06
JP5057273B2 (ja) 2012-10-24
US20080261917A1 (en) 2008-10-23
AU2005278962B2 (en) 2012-03-01
EP1786773A1 (en) 2007-05-23
JP2008511601A (ja) 2008-04-17
US8258175B2 (en) 2012-09-04

Similar Documents

Publication Publication Date Title
AU2005278962C1 (en) Isoindolin-1-one derivatives
RU2155187C2 (ru) Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
CA2766328C (en) Isoindolin-1-one derivatives
EP0673937B1 (en) Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
CA2598788C (en) Indoline-sulfonamides compounds
US20030153507A1 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
AU2002345644A1 (en) HV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HU213605B (en) Process for producing amide composition and pharmaceutical compositions comprising same as active ingredient
BG109688A (bg) Карбоксиарил заместени дифенил уреи като инхибитори на raf киназа
JP5778297B2 (ja) 癌治療用のｈｄａｃ阻害剤としての新規４−アミノ−ｎ−ヒドロキシ−ベンズアミド
HK1203943A1 (en) Quinazolinedione derivative
US7750019B2 (en) Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
KR100686531B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 아릴아미노메틸프로페닐 벤즈하이드록시아마이드 유도체 및 그의 제조방법
JPS609716B2 (ja) １，２―ベンズインチアゾリン―３―オン類、それらの製造法および医薬としての使用
CN111763180B (zh) 苯并氮杂环类化合物及其制法和药物用途
CA2787860C (en) Substituted 2-imidazolidones and analogs and their use against cancer
US20250026741A1 (en) Inhibitors of the oncogenic shp2 phosphatase and uses thereof
JPH06220044A (ja) ベンズアミド誘導体
JPH07149722A (ja) 縮合複素環化合物、その製造法および剤
JPH059429B2 (enExample)
JPH0328425B2 (enExample)
AU2006235964A1 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HARDCASTELE, IAN ROBERT; GOLDING, BERNARD THOMAS; CALVERT, ALAN H.; NOBEL, MARTIN E. M.; WILLEMS, HENDRIKA MARIA GERARDA; GRIFFIN, ROGER JOHN; LUNEC, JOHN; NEWELL, DAVID R. AND KALLBLAD, PER.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2012 .

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WILLEMS, HENDRIKA MARIA GERARDA; KALLBLAD, PER; HARDCASTLE, IAN ROBERT; GRIFFIN, ROGER JOHN; GOLDING, BERNARD THOMAS; LUNEC, JOHN; NOBEL, MARTIN E. M.; NEWELL, DAVID R. AND CALVERT, ALAN H. .

TH Corrigenda

Free format text: IN VOL 26 , NO 22 , PAGE(S) 2980 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS DELETE ALL REFERENCE TO 2005278962

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 MAY 2012

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ WILLEMS, HENDRIKA MARIA GERARDA; KALLBLAD, PER; HARDCASTLE, IAN ROBERT; GRIFFIN, ROGER JOHN; GOLDING, BERNARD THOMAS; LUNEC, JOHN; NOBEL, MARTIN E. M.; NEWELL, DAVID R. AND CALVERT, ALAN H.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired